Migdal Insurance & Financial Holdings Ltd. Zai Lab LTD Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.97 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$81.94 - $135.34 $307,029 - $507,118	-3,747 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$73.3 - $89.48 $139,050 - $169,743	1,897 Added 102.54%	3,747 $309,000
Q2 2020 Aug 11, 2020	BUY	$48.82 - $82.53 $90,317 - $152,680	1,850 New	1,850 $153,000

Others Institutions Holding ZLAB

# of Institutions

146

Shares Held

53M

Call Options Held

103K

Put Options Held

439K

Wellington Management Group LLP Boston, MA

6.66M
Shares

$231 Million
0.03% of portfolio
Janus Henderson Group PLC London, X0

6.57M
Shares

$228 Million
0.09% of portfolio
Capital World Investors Los Angeles, CA

6.43M
Shares

$223 Million
0.03% of portfolio
Morgan Stanley New York, NY

3.17M
Shares

$110 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

2.51M
Shares

$87 Million
1.07% of portfolio

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.4B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account